Browse hierarchy: [Immunology (IM)](/submissions/IM) → [Subpart F — Immunological Test Systems](/submissions/IM/subpart-f%E2%80%94immunological-test-systems) → [21 CFR 866.5840](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/866.5840) → QSE — Alzheimer’S Disease Pathology Assessment Test

# QSE · Alzheimer’S Disease Pathology Assessment Test

_Immunology · 21 CFR 866.5840 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/QSE

## Overview

- **Product Code:** QSE
- **Device Name:** Alzheimer’S Disease Pathology Assessment Test
- **Regulation:** [21 CFR 866.5840](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/866.5840)
- **Device Class:** 2
- **Review Panel:** [Immunology](/submissions/IM)

## Identification

In vitro test to determine whether a patient presenting with cognitive impairment and being evaluated for AD and other causes of cognitive decline will test positive or negative for amyloid plaques or neurofibrillary tangles as measured by PET imaging agents.

## Recent Cleared Devices (3 of 3)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K231348](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/QSE/K231348.md) | Elecsys ß-Amyloid (1-42) CSF II, Elecsys Total-Tau CSF | Roche Diagnostics | Jun 5, 2023 | SESE |
| [K221842](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/QSE/K221842.md) | Elecsys B-Amyloid (1-42) CSF II, Elecsys Phospho-Tau (181P) CSF | Roche Diagnostics | Dec 7, 2022 | SESE |
| [DEN200072](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/QSE/DEN200072.md) | Lumipulse G ß-Amyloid Ratio (1-42/1-40) | Fujirebio Diagnostics,Inc. | May 4, 2022 | DENG |

## Top Applicants

- Roche Diagnostics — 2 clearances
- Fujirebio Diagnostics,Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/QSE](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/QSE)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com